BCRX Stock BioCryst Pharmaceuticals (BCRX, $6.31) Aroon Indicator entered an Uptrend on June 07, 2024.

GET DAILY SIGNALS

Get AI intraday signals

BCRX - BioCryst Pharmaceuticals

Aroon signal

View

Odds of UP Trend

Price: $6.31

Daily change: -$0.13 (-2.02%)

Daily volume: 3.3M

Capitalization: $1.3B

Industry: Biotechnology

BCRX sees its Stochastic Oscillator ascends from oversold territory

On November 21, 2024, the Stochastic Oscillator for BCRX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 29, 2024. You may want to consider a long position or call options on BCRX as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BCRX just turned positive on December 05, 2024. Looking at past instances where BCRX's MACD turned positive, the stock continued to rise in of 58 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for BCRX crossed bullishly above the 50-day moving average on December 16, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BCRX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

BCRX moved below its 50-day moving average on December 12, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BCRX broke above its upper Bollinger Band on December 10, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.626). P/E Ratio (0.000) is within average values for comparable stocks, (87.424). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). BCRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.726) is also within normal values, averaging (260.938).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.